VWM
REGN icon

Valley Wealth Managers’s Regeneron Pharmaceuticals REGN Stock Holding History

Valley Wealth Managers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47
Closed -$29.8K – 365
2025
Q1 		$29.8K Hold
47
– – ﹤0.01% 228
2024
Q4 		$33.5K Hold
47
– – ﹤0.01% 233
2024
Q3 		$49.4K Buy
+47
New +$52.3K ﹤0.01% 217

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Valley Wealth Managers's REGN Position: Q2 2025 in Review

Valley Wealth Managers sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 47 shares — an estimated $29.8K sold.

Valley Wealth Managers first reported a position in REGN in Q3 2024 and held it in 3 quarters. The position peaked at $49.4K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Valley Wealth Managers reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Valley Wealth Managers sold 47 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $29.8K.
  • Valley Wealth Managers first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Valley Wealth Managers's Regeneron Pharmaceuticals position peaked at $49.4K in Q3 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Valley Wealth Managers's 13F filing for Q2 2025, filed 6 Aug 2025.